Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Common genomic alterations recommended for inclusion in a comprehensive

Cancers, Free Full-Text

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study, Molecular Cancer

Cancers, Free Full-Text

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Cancers, Free Full-Text

PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Cancers, Free Full-Text

Mutation profile of non-small cell lung cancer revealed by next generation sequencing, Respiratory Research

Mutation profile of non-small cell lung cancer revealed by next generation sequencing, Respiratory Research

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma - ScienceDirect

Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology, Genome Medicine

PDF) TERT Mutations in Non–Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Implications